Laurie Halloran founded Halloran Consulting Group in 1998, originally operating out of an unfinished bathroom. Her time as a pediatric ICU nurse had inspired her to start a company that helps move new therapies through FDA processes to get them into the hands of patients desperately in need. By providing a strategic development team, innovative start-up companies could have access to world-class expertise at a fraction of the cost. Since its humble beginnings, Halloran has grown into a successful consultancy of like-minded experts who are dedicated to improving human health by making life science companies better at what they do. Laurie has been named 2018 Women’s Business Enterprise Star by the Women's Business Enterprise National Council (WBENC) and has won a 2017 Enterprising Women of the Year Award from Enterprising Women Magazine. Halloran Consulting Group was also named an Inc. 5000 Fastest Growing Company for the past three years in a row. In 2015, Laurie was honored by the Boston Business Journal as a Woman of Influence, in 2010 was selected as one of the 100 Most Inspiring People in Life Science by PharmaVoice, and in 2009, she was awarded Clinical Researcher of the Year by the New England Chapter of the Associate of Clinical Research Professionals. Laurie lectures at Boston University Medical School and the Tufts Center for Drug Development Post-Graduate program. She has previously taught at George Washington University and Harvard University. Laurie earned a Bachelor of Science in nursing from Russell Sage College and a Master of Science in management from Lesley University. She is also a Prosci Certified Change Practitioner.

Jennifer Petrillo Billet PhD is a Director at Sage Therapeutics in the Department for Health Economics and Outcomes Research and Value Demonstration, based in Cambridge MA. She leads the HEOR strategy for the NMDA portfolio, which is exploring indications in Huntington’s Disease, Alzheimer’s Disease, and Cognitive Impairment in Parkinson’s Disease. She is responsible for driving the Global strategy, including identifying patient-centric outcomes measures relevant to patients, payers, and providers. Jennifer has over 15 years of deep expertise in COA qualitative and quantitative analyses focusing on the US and EU markets, translating benefits for patient access. She has considerable expertise in the development and qualification of Clinical Outcomes Assessments (COAs) across all disease areas. As a research assistant on the only qualified COA listed under the FDA’s Drug Development Tool Qualification Program, the EXACT-PRO, she led drug sponsors, clinicians, academics, and the FDA to develop a daily diary to measure exacerbations of chronic obstructive pulmonary disease (COPD). This experience remains transformative, in terms of FDA awareness and payer relevance, in how she drives other COA strategy initiatives for Sage. Jennifer received her Bachelor of Science degree in Economics from the Pamplin College of Business at Virginia Tech, and her PhD in Health Services Research and Policy from the London School of Hygiene and Tropical Medicine. She has published and presented extensively on COA/PRO instruments and utilities, across a range of leading journals including Chest, Clinical Gastroenterology and Hepatology, Current Medical Research and Opinion, JAMA Ophthalmology, Neuro-Ophthalmology, MS Journal, Pharmacoeconomics, Quality of Life Research, and Value in Health.

Laura E. Randa serves as Chief Executive Officer for Randa BioPharma Solutions, a boutique consulting firm focused on building start-up life sciences companies, advancing pipeline and in-line assets by providing transformative solutions for the life sciences industry. Ms. Randa serves as a Strategic Advisor and Member of the Advisory Board of Tutela Pharmaceuticals, a nonprofit company targeting continued access and affordability of single-source marketed pharmaceuticals. She also is a Strategic Advisor and Member of the Advisory Board of Emedgene which is operating the world’s first completely automated genetic interpretation platform. She is a founding member of the American Association of People with Disabilities’ new Disability Advisory Roundtable. She serves as Co-Chair of the Executive Women in Business Capital Region, Women’s Health Executive Committee and Life Science Council Board member at Springboard Enterprises and serves as a strategic advisor to the CEO and Founder Hello Career Guru.

Alex is currently the Senior Vice President of Market Access at Nektar Therapeutics where he is responsible for ensuring commercial readiness for their first commercial product launch. In this role Alex is responsible for Payer Marketing, Channel Management, Pricing, Contracting, Patient Services, Account Management, and Reimbursement Support. Prior to joining Nektar in October, 2020 he was at Lexicon Pharmaceuticals for 5.5 years where he held the position EVP, Chief Commercial Officer responsible for leading all aspects of the commercial organization to include Sales, Marketing, Market Access, and Business Analytics. Before joining Lexicon Pharmaceuticals in 2015, Alex was at Bayer Healthcare where he held the position of EVP, US Market Access responsible for Payer Marketing, Pricing & Contracting, Channel Management , Account Management , and Patient Services. In this role, as an US Executive Committee member he also represented US Market Access function on the Global Leadership Committee, a committee comprised of 250 senior executives worldwide. Innovative and results driven healthcare executive focused on achieving exceptional results in highly competitive environments that demand continuous improvement. With over 30 years of varied health care experience Alex has demonstrated ability to build, lead, and motivate cross functional teams that exceed corporate expectations. Experienced in driving successful product launches and customer service improvements while building strategic partnerships with key decision makers both externally and internally within an organization. Successfully launched numerous brands in diverse specialty therapeutic categories with all brands meeting and/or exceeding all market launch objectives.